Month: October 2023

Next Generation RNA Therapeutics and Vaccines – A Marvel of The Lifesciences Industry

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions. In addition, they offer enhanced therapeutic and safety profiles as compared to traditional treatment approaches. However,

Decentralized Clinical Trials: The Future of Clinical Research

Over the past decade, the rise of this digital technology has transformed various sectors, from finance to healthcare. One particular area that has seen significant innovation is the realm of clinical trials. Traditionally conducted at centralized sites like hospitals or clinics, the latest trend is moving towards decentralized clinical trials (DCTs). Clinical trials are prospective

Injected Version of Eisai/Biogen Alzheimer’s Drug Works as Well as IV Leqembi

On 26 October 2023, Eisai and Biogen’s Alzheimer’s drug, Leqembi, was found to be as effective as the current intravenous administration in removing toxic brain plaques. However, the review conducted by the drugmakers revealed that the rates of serious side effects were higher when using the drug in its subcutaneous injection form. The company’s analysis

BioNtech Reports Preliminary Phase I/II Results of its CAR T Cell Therapy CarVAC and BNT211-01 (NEO-PTC-01) at European Society for Medical Oncology (ESMO) Conference

On 24 October 2023, BioNtech announced the preliminary results of phase I/II trial evaluating BNT.221-01, a combination of Claudin 6 (CLDN6)-targeted CAR T cell therapy and the mRNA-based CAR T booster CarVac at ESMO conference in Madrid. BioNtech reported acceptable safety and tolerability data and first hints to efficacy in solid tumours. The CAR T

Merck Enters into a Development Agreement with Daiichi for Antibody Drug Conjugates

On 23 October 2023, Merck announced a development agreement for Daiichi Sankyo’s clinical-phase antibody-drug conjugate, namely patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd), targeting cancer. Merck has invested $5.5 billion to jointly develop three of its candidate cancer drugs and is likely to invest up to $22 billion in addition depending on

Single-use Bioreactor: An Indispensable Component for Biopharmaceutical Manufacturing

The limitations of stainless-steel bioreactors such as high risk of contamination, process related challenges and high operational cost have prompted innovators to develop more advanced single use bioreactor in order to meet the rising demand for safe and efficacious biotherapeutics. Conventional stainless-steel bioreactors require more energy as compared to the single use bioreactor for sterilization,

HPAPIs – Current Interest of the Pharmaceutical Industry

Owing to the advancement in clinical pharmacology and oncology domain, and the rising demand for targeted therapeutics and precision medicines, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have become one of the key areas of interest to researchers and drug manufacturers across the globe. HPAPIs, due to their selective mode of action, are

RNA Therapeutics: A Novel Approach to Treating Diseases

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. These therapeutics are broadly classified into two categories, namely coding RNAs and non-coding RNAs. Coding RNAs include messenger RNA

Bacteriophage Therapy – A Revolutionary Approach Towards Multi-Resistant Bacteria

Bacteria plays a crucial role in maintaining the ecosystem balance. However, there are few species of bacteria that can cause several infectious diseases (such as strep throat, salmonellosis, tuberculosis, whooping cough). These are mainly transmitted through air, water, living organisms, and food. Further, the spread of infections to a larger population is attributed to the

Biopharmaceutical Filtration: A Deep Dive

Biopharmaceutical filtration is a critical step in the production of biopharmaceuticals, including proteins, antibodies, and vaccines. It involves the separation of unwanted particles from biological materials to obtain contaminant free products. Filtration plays a crucial role in ensuring the safety, efficacy, and quality of biopharmaceutical products. The biopharmaceutical industry uses different filtration systems depending on

Can The Next Generation Drug Conjugates Revolutionize The Rare Disorder Domain?

Over the last two decades the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to more enhanced, potent, and targeted therapeutics. This led the researchers to find alternative pathways and drug delivery strategies to enhance the potent delivery of the drug to the site of action. As a result, in late

Berkus Method of Start-up Valuation to Evaluate Start-ups Engaged in Digital Twins Domain

Digital twins is a rapidly emerging space and there are several start-ups working to provide novel solutions. In this article, we’ve looked at a method of company valuation. Berkus start-up valuation is a method developed by the American venture capitalist and angel investor, Dave Berkus in the mid 1990’s. The Berkus method was designed to

Agricultural Biologicals: An Answer to a Sustainable Future

The introduction of the Green Revolution in the late 1960s led to a substantial agricultural intensification. The primary objective of the initiative was to feed a growing population with limited land resources and enhanced crop yields. Consequently, the use of agrochemicals, such as chemical pesticides and fertilizers, became an integral part of this industrialized approach.

Pharmaceutical Polymers / Medical Polymers -Current Scenario and Future Potential

Driven by the increasing need for safe and efficient medical devices and drug delivery systems, the pharmaceutical polymers / medical grade polymers domain is advancing significantly. There has been a rise in the development of polymers for biopharma with improved biocompatibility, biodegradability and functionality. It is worth highlighting that the manufacturing of polymers for biopharma

Bioreactor Industry: Current Scenario and Future Trends

Bioreactors and fermenters are complex systems used across numerous sectors of the industry, for the production of pharmaceuticals, nutraceuticals, food, and beverages. These systems provide controlled conditions for cell growth by providing optimum nutrient supply, and oxygenation, enabling the production of biologics. Bioreactors and fermenters can range from small laboratory-scale to industrial-scale systems, and may

Nanoparticle Formulation: A Paradigm Shift towards Novel Drug Delivery

Nanoparticles (zero-dimensional nanomaterials) are ultra-fine particles with overall dimension ranging between 1-100 nm. Owing to their unique size and physicochemical properties (surface roughness, surface area, surface energy, crystal structure and shape), nanoparticles can be widely used as a contrasting agent in medical imaging, a vesicle to cross the blood-brain barrier and a carrier for targeted